Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Thomas Kirwin who wrote (34)	3/11/1998 11:30:00 PM
From: Mason Barge	Respond to of 422

I've heard a couple of people speculate about this from time to time (not the current J&J rumor, that's news to me) and my reaction is disdain. Immucor has spend two years doing the pre-marketing for the ABS series and I don't want my massive gains diluted by an acquisition. The company management is quite sound and I think they can make more money -- and a higher share price -- by themselves. Because of the extensive inside ownership, though, I have some degree of faith that there won't be a takeover unless managment thinks the terms are favorable In other words, if the ABS 2000 is approved, I'm not selling my Immucor for $20 a share. I think it will be worth more. In fact, if we're lucky, some big momentum players will get involved and drive the price up into the 30's. Your greedy amigo, Mason

To: Thomas Kirwin who wrote (34)	3/12/1998 3:28:00 AM
From: technetx	Read Replies (3) \| Respond to of 422

I have been a shareholder in BLUD for over three years. If you have seen some of my posts to the boards (AOL mostly), I have come to the conclusion , about a year ago, that BLUD cannot handle the demand for the ABS2000. BLUD needs help in the form of a big cap partner offering a distribution agreement. OR BLUD must go...allow itself to be bought out by a big player; like Abbot, J&J, Bectin-Dickenson, Etc. etc. I differ slightly with Mason's opinion that BLUD can bring in big profits with the ABS. Yes the demand is there, but the potential to deliver is not up to the job. I believe BLUD can see an EPS of $1 in the first year...translates to about $30- 35 share price. But a big cap company could probably do three times the sales or more of ABS units in the first year. According to Ed Gallup, CEO, BLUD has about a 3 year window of exclusivity in the automated blood typing (ABS) arena....then competitors may emerge. BLUD needs help to saturate the ABS market with units fairly quickly. According to Gallup, told to me in a conference call I participated in about 9 months or a year ago, BLUD can place about 1 ABS unit per week in the first 6 months and then 2 or 3 units per week in the next 6 months. This doesn't even begin to satisfy the market. I believe a buy out is the most likely scenario. One other thing I learned in the conference call: J&J at that time announced that they have terminated efforts to produce a blood typing (ABS type) device to compete with BLUD. My analysis: a buy out is a lot cheaper than R&D. J&J is, or at least was, industry leader in the blood test reagent business. With the advent of the ABS, J&J's leadership is sure to be lost. J&J doesn't like to be second best in anything. They buy companies all the time. ..remember their net profit is in the billions each year. To buy BLUD at 30 or 40 per share X 8 million shares = pocket change ! Dominic